NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by

Investment analysts at started coverage on shares of NovaBay Pharmaceuticals (NYSE:NBYGet Rating) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

Separately, Ascendiant Capital Markets lowered their target price on NovaBay Pharmaceuticals from $4.25 to $4.00 and set a “buy” rating on the stock in a report on Friday, May 20th.

NYSE NBY opened at $0.22 on Tuesday. NovaBay Pharmaceuticals has a 12 month low of $0.17 and a 12 month high of $0.88. The stock has a market capitalization of $11.39 million, a PE ratio of -1.97 and a beta of 3.30. The business has a fifty day moving average of $0.23.

NovaBay Pharmaceuticals (NYSE:NBYGet Rating) last released its quarterly earnings data on Tuesday, March 29th. The company reported ($0.02) EPS for the quarter. NovaBay Pharmaceuticals had a negative net margin of 47.80% and a negative return on equity of 37.44%. The business had revenue of $2.64 million for the quarter. On average, equities analysts expect that NovaBay Pharmaceuticals will post -0.09 earnings per share for the current year.

NovaBay Pharmaceuticals Company Profile (Get Rating)

NovaBay Pharmaceuticals, Inc, a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. It offers Avenova, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products under the NeutroPhase and PhaseOne brands.

Featured Stories

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with's FREE daily email newsletter.